Latest Headlines

  1. Quest Diagnostics Unveils Advanced Transplant Diagnostic Services Featuring Anywhere-Access In The United States 3/22/2023

    Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled a comprehensive suite of advanced diagnostics and support services designed to broaden access to laboratory tests for transplanting solid organ, human cells and tissue.

  2. CND Life Sciences Enters Into Licensing And Collaboration Agreement To Advance Diagnostic Technology For Neurodegenerative Diseases 3/22/2023

    CND Life Sciences, a medical technology company pioneering the development of highly accurate skin-based tests to help clinicians diagnose neurodegenerative disorders like Parkinson's disease and dementia with Lewy bodies, has entered into a licensing collaboration with Beth Israel Deaconess Medical Center (BIDMC) in Boston to advance CND's scientific platform and patient-focused mission.

  3. Trinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm 3/22/2023

    Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today welcomed the announcement by the Kenyan Ministry of Health of the adoption of a new HIV rapid testing algorithm.

  4. First-Of-Its-Kind Post-COVID-19 Panels Available At questhealth.com 3/21/2023

    The consumer-initiated testing business from the leader in diagnostic testing, Quest Diagnostics (NYSE: DGX), has introduced two innovative Post-COVID-19 panels.

  5. Cue Health Receives FDA Emergency Use Authorization For Molecular Mpox Test 3/20/2023

    Cue Health (“Cue”), a healthcare technology company, today announced it has received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for its molecular test to detect the mpox virus (formerly known as monkeypox). 

  6. Oxford Nanopore And 4bases Announce Collaboration To Combine Nanopore Sequencing Devices And 4bases Kits To Support Rapid, High-Accuracy Analyses In Human And Cancer Genetics, With A First Target Of Same-Day BRCA1 And BRCA2 Analysis 3/20/2023

    Oxford Nanopore Technologies plc (Oxford Nanopore) and 4bases, a Switzerland-based company, specialising in kits for sequencing and bioinformatic tools, today announce a collaboration to make available 4bases kits with Oxford Nanopore sequencing technology.

  7. GENETWORx Looking To Acquire Or Partner With Diagnostic Laboratories 3/17/2023

    GENETWORx, a private equity backed laboratory, announces it’s looking to buy or partner with other diagnostics laboratories.

  8. Sensitive HPLC Refractive Index Detector 3/16/2023

    Biotech Fluidics announce REFRACTiMASTER - a new HPLC refractive index (RI) detector suitable for detecting compounds with little or no UV activity including simple sugars, complex carbohydrates, alcohols, fatty acids, and polymers.

  9. Rapid Novor’s Blood Test For Multiple Myeloma Monitoring Is CLIA Certified For Clinical Use In The US 3/16/2023

    Rapid Novor Inc., the world’s leader in mass spectrometry (MS)-based antibody protein sequencing, announced today that its diagnostic laboratory obtained the Clinical Laboratory Improvement Amendments (CLIA) certification for their EasyM™ assay as a Laboratory Developed Test (LDT).

  10. BD Receives FDA 510(k) Clearance For First-Of-Its-Kind High-Throughput Diagnostic Test For Infectious Vaginitis 3/16/2023

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Vaginal Panel on the BD COR™ System, a comprehensive diagnostic test that directly detects the three most common infectious causes of vaginitis using BD's high-throughput molecular diagnostic platform for large laboratories.